{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson%27s+Disease%2C+Idiopathic",
    "query": {
      "condition": "Parkinson's Disease, Idiopathic"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 79,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson%27s+Disease%2C+Idiopathic&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T12:25:57.607Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03074812",
      "title": "Exploring Mechanisms for Neuropsychiatric Symptoms of Parkinson Disease Using Transcranial Direct Current Stimulation",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Idiopathic Parkinson's Disease",
        "Parkinson Disease",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Transcranial Direct Current Stimulation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 80,
      "start_date": "2016-02",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-06-10T12:25:57.607Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03074812"
    },
    {
      "nct_id": "NCT03257046",
      "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "ITI-214",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Intra-Cellular Therapies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2017-09-28",
      "completion_date": "2018-09-28",
      "has_results": false,
      "last_update_posted_date": "2018-12-20",
      "last_synced_at": "2026-06-10T12:25:57.607Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Durham, North Carolina",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03257046"
    },
    {
      "nct_id": "NCT00519532",
      "title": "Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Rotigotine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2007-07",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2014-10-27",
      "last_synced_at": "2026-06-10T12:25:57.607Z",
      "location_count": 2,
      "location_summary": "St. Petersburg, Florida • Salisbury, North Carolina",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Salisbury",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00519532"
    },
    {
      "nct_id": "NCT02352363",
      "title": "Randomized Safety Study of CVT-301 Compared to an Observational Control Group",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Idiopathic Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "CVT-301",
          "type": "DRUG"
        },
        {
          "name": "Observational cohort",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Acorda Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 408,
      "start_date": "2015-03",
      "completion_date": "2017-05",
      "has_results": true,
      "last_update_posted_date": "2019-05-28",
      "last_synced_at": "2026-06-10T12:25:57.607Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Fountain Valley, California • Panorama City, California + 10 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Panorama City",
          "state": "California"
        },
        {
          "city": "Sunnyvale",
          "state": "California"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02352363"
    },
    {
      "nct_id": "NCT01931644",
      "title": "At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "All Diagnosed Health Conditions",
        "ADD/ADHD",
        "Alopecia Areata",
        "Ankylosing Spondylitis",
        "Asthma",
        "Atopic Dermatitis Eczema",
        "Beta Thalassemia",
        "Bipolar Disorder",
        "Breast Cancer",
        "Celiac Disease",
        "Cervical Cancer",
        "Chronic Inflammatory Demyelinating Polyneuropathy",
        "Chronic Kidney Diseases",
        "Chronic Obstructive Pulmonary Disease",
        "Colon Cancer",
        "Colorectal Cancer",
        "Crohn's Disease",
        "Cystic Fibrosis",
        "Depression",
        "Diabetes Mellitus",
        "Duchenne Muscular Dystrophy",
        "Endometriosis",
        "Epilepsy",
        "Facioscapulohumeral Muscular Dystrophy",
        "G6PD Deficiency",
        "General Anxiety Disorder",
        "Hepatitis B",
        "Hereditary Hemorrhagic Telangiectasia",
        "HIV/AIDS",
        "Human Papilloma Virus",
        "Huntington's Disease",
        "Idiopathic Thrombocytopenic Purpura",
        "Insomnia",
        "Kidney Cancer",
        "Leukemia",
        "Lung Cancer",
        "Lupus Nephritis",
        "Lymphoma",
        "Melanoma",
        "Multiple Myeloma",
        "Multiple Sclerosis",
        "Myositis",
        "Myotonic Dystrophy",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Parkinson's Disease",
        "Polycystic Kidney Diseases",
        "Prostate Cancer",
        "Psoriasis",
        "Psoriatic Arthritis",
        "Rosacea",
        "Scleroderma",
        "Sickle Cell Anemia",
        "Sickle Cell Trait",
        "Sjogren's Syndrome",
        "Skin Cancer",
        "Spinal Muscular Atrophy",
        "Systemic Lupus Erythematosus",
        "Thrombotic Thrombocytopenic Purpura",
        "Trisomy 21",
        "Ulcerative Colitis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Sanguine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 17667,
      "start_date": "2013-07",
      "completion_date": "2024-04",
      "has_results": false,
      "last_update_posted_date": "2024-04-18",
      "last_synced_at": "2026-06-10T12:25:57.607Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01931644"
    },
    {
      "nct_id": "NCT02246374",
      "title": "ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "ExAblate Transcranial System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "InSightec",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2014-09",
      "completion_date": "2021-05-18",
      "has_results": false,
      "last_update_posted_date": "2026-04-20",
      "last_synced_at": "2026-06-10T12:25:57.607Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02246374"
    },
    {
      "nct_id": "NCT02373072",
      "title": "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "PF-06649751",
          "type": "DRUG"
        },
        {
          "name": "Trimethobenzamide Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 18,
      "start_date": "2015-03",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2023-09-22",
      "last_synced_at": "2026-06-10T12:25:57.607Z",
      "location_count": 7,
      "location_summary": "Long Beach, California • Hallandale, Florida • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Elkridge",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02373072"
    },
    {
      "nct_id": "NCT01772693",
      "title": "ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "ExAblate Transcranial MRgFUS",
          "type": "DEVICE"
        },
        {
          "name": "Sham ExAblate Transcranial MRgFUS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "InSightec",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2012-09",
      "completion_date": "2019-03",
      "has_results": true,
      "last_update_posted_date": "2020-10-09",
      "last_synced_at": "2026-06-10T12:25:57.607Z",
      "location_count": 2,
      "location_summary": "Charlottesville, Virginia • Seattle, Washington",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01772693"
    },
    {
      "nct_id": "NCT04459052",
      "title": "FDOPA PET and Nutritional Support in Parkinson's Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease",
        "Idiopathic Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "N acetyl cysteine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "[F-18] Fluorodopa Positron Emission Tomography",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2020-04-30",
      "completion_date": "2027-01-08",
      "has_results": false,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-06-10T12:25:57.607Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04459052"
    },
    {
      "nct_id": "NCT00163085",
      "title": "The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "NR2B NMDA Antagonist CP-101,606 (traxoprodil)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 12,
      "start_date": "2005-05",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2006-09-22",
      "last_synced_at": "2026-06-10T12:25:57.607Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00163085"
    }
  ]
}